STRUCTURE THERAPEUTICS INC (GPCR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$21.19-3.37%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge STRUCTURE THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.509
Annual ending 2026-12-31
Revenue	—	38.46M
EPS	—	-1.666
Annual ending 2027-12-31
Revenue	—	45,455
EPS	—	-2.146

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Stability and effectiveness of new COO and General Counsel	The company strengthened its leadership by appointing a new COO and General Counsel.	Intact	COO or General Counsel turnover or failure to improve operations by end 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Effective execution of amended sales agreement and capital allocation	Amended sales agreements improve capital strategies.	Intact	Failure to implement amended sales agreement effectively by end 2026	Amended Sales Agreement implemented (May 2026) vs 2026-12-31 target May 2026 entry into Amended and Restated Sales Agreement with Leerink and Cantor confirms successful implementation. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Initiate Phase 3 trials for aleniglipron in 2H 2026	Structure Therapeutics is advancing its key drug to Phase 3 trials in the second half of 2026.	Improving	Phase 3 trials not initiated by end of 2026	Phase 3 initiation pending vs 2H 2026 target June 2026 positive Phase 2 data for aleniglipron; no Phase 3 initiation announcement or delay reported as of Oct 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.15

$-1.98 → $-2.15 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.98	$55,556	9 / 12
2026-07-25	$-1.98	$55,556	9 / 12
2026-07-26	$-2.08	$41,670	11 / 12
2026-07-27	$-2.08	$41,670	11 / 12
2026-07-28	$-1.98	$55,556	9 / 12
2026-07-29	$-2.08	$41,670	11 / 12
2026-07-30	$-2.08	$41,670	11 / 12
2026-07-31	$-2.08	$41,670	11 / 12
2026-08-01	$-1.98	$55,556	9 / 12
2026-08-02	$-2.08	$41,670	11 / 12
2026-08-03	$-2.08	$41,670	11 / 12
2026-08-04	$-2.08	$41,670	11 / 12
2026-08-05	$-2.08	$41,670	11 / 12
2026-08-06	$-1.98	$55,556	9 / 12
2026-08-07	$-1.98	$55,556	9 / 12
2026-08-08	$-2.04	$45,450	10 / 11
2026-08-09	$-2.04	$45,450	10 / 11
2026-08-10	$-2.04	$45,450	10 / 11
2026-08-12	$-1.98	$55,556	9 / 12
2026-08-13	$-1.98	$55,556	9 / 12
2026-08-14	$-1.98	$55,556	9 / 12
2026-08-15	$-1.98	$55,556	9 / 11
2026-08-16	$-1.98	$55,556	9 / 11
2026-08-17	$-1.98	$55,556	9 / 11
2026-08-18	$-1.98	$55,556	9 / 12
2026-08-19	$-1.98	$55,556	9 / 12
2026-08-20	$-2.11	$45,455	8 / 12
2026-08-21	$-2.11	$45,455	8 / 12
2026-08-22	$-2.11	$45,455	8 / 12
2026-08-23	$-2.11	$45,455	8 / 12
2026-08-24	$-2.11	$45,455	8 / 12
2026-08-25	$-2.11	$45,455	8 / 12
2026-08-26	$-2.11	$45,455	8 / 12
2026-08-27	$-2.11	$45,455	8 / 12
2026-08-28	$-2.11	$45,455	8 / 12
2026-08-29	$-2.11	$45,455	8 / 12
2026-08-30	$-2.11	$45,455	8 / 12
2026-08-31	$-2.11	$45,455	8 / 12
2026-09-01	$-2.11	$45,455	8 / 12
2026-09-02	$-2.11	$45,455	8 / 12
2026-09-03	$-2.11	$45,455	8 / 12
2026-09-04	$-2.11	$45,455	8 / 12
2026-09-05	$-2.12	$45,455	8 / 12
2026-09-06	$-2.12	$45,455	8 / 12
2026-09-07	$-2.12	$45,455	8 / 12
2026-09-08	$-2.12	$45,455	8 / 12
2026-09-09	$-2.12	$45,455	8 / 12
2026-09-10	$-2.12	$45,455	8 / 12
2026-09-11	$-2.12	$45,455	8 / 12
2026-09-12	$-2.12	$45,455	8 / 12
2026-09-13	$-2.12	$45,455	8 / 12
2026-09-14	$-2.12	$45,455	8 / 12
2026-09-15	$-2.12	$45,455	8 / 12
2026-09-16	$-2.12	$45,455	8 / 12
2026-09-17	$-2.12	$45,455	8 / 12
2026-09-18	$-2.12	$45,455	8 / 12
2026-09-19	$-2.12	$45,455	8 / 12
2026-09-20	$-2.15	$45,455	8 / 12
2026-09-21	$-2.15	$45,455	8 / 12
2026-09-22	$-2.15	$45,455	8 / 12
2026-09-23	$-2.15	$45,455	8 / 12
2026-09-24	$-2.15	$45,455	8 / 12
2026-09-25	$-2.15	$45,455	7 / 11
2026-09-26	$-2.15	$45,455	7 / 11
2026-09-27	$-2.15	$45,455	7 / 11
2026-09-28	$-2.15	$45,455	7 / 11
2026-09-29	$-2.15	$45,455	7 / 11
2026-09-30	$-2.15	$45,455	7 / 11
2026-10-01	$-2.15	$45,455	7 / 11
2026-10-02	$-2.15	$45,455	6 / 11
2026-10-03	$-2.15	$45,455	6 / 11
2026-10-04	$-2.15	$45,455	6 / 11
2026-10-05	$-2.15	$45,455	6 / 11
2026-10-06	$-2.15	$45,455	7 / 11
2026-10-07	$-2.15	$45,455	7 / 11
2026-10-08	$-2.15	$45,455	7 / 11
2026-10-09	$-2.15	$45,455	7 / 11
2026-10-10	$-2.15	$45,455	7 / 11
2026-10-11	$-2.15	$45,455	7 / 11
2026-10-12	$-2.15	$45,455	7 / 11
2026-10-13	$-2.15	$45,455	7 / 11
2026-10-14	$-2.15	$45,455	7 / 11
2026-10-15	$-2.15	$45,455	7 / 11
2026-10-16	$-2.15	$45,455	7 / 11
2026-10-17	$-2.15	$45,455	7 / 11
2026-10-18	$-2.15	$45,455	7 / 11
2026-10-19	$-2.15	$45,455	7 / 11
2026-10-20	$-2.15	$45,455	7 / 11
2026-10-21	$-2.15	$45,455	7 / 11
2026-10-22	$-2.15	$45,455	7 / 11
2026-10-23	$-2.15	$45,455	7 / 11
2026-10-24	$-2.15	$45,455	7 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	16	1
2026-06-01	16	1
2026-07-01	16	1
2026-08-01	15	1
2026-09-01	15	1
2026-10-01	15	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 15 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stability and effectiveness of new COO and General CounselQualitative condition

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-77.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

STRUCTURE THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage growth story, not a proven earnings compounder. The thesis is in watch status: key trials are progressing, but recent performance is below its industry cohort and the evidence snapshot has low overall confidence.

What's priced into STRUCTURE THERAPEUTICS INC

The snapshot provides no valuation level or specific market expectations, so it is not possible to judge whether GPCR looks cheap, fair, or expensive versus peers. It does report low fragility, but that does not establish what expectations are already reflected in the valuation.

What the fundamentals likely do

Over the multi-year view, Phase 3 trials for aleniglipron are underway, with topline data expected in the second half of 2028; cash reserves are expected to fund operations and key clinical milestones through 2028. Early amylin-program data are positive, while the new commercial leader’s impact is not yet reflected in financial measures. Near term, consecutive earnings misses and an elevated chance of another miss are risks; a sector backdrop that has improved is a counterweight, not a company-specific fix.

What STRUCTURE THERAPEUTICS INC hinges on

The thesis depends on steady trial progress and whether upcoming clinical milestones support the programs’ development. A guidance cut, continued weak employment data, or further earnings misses could weigh on the setup; stronger results and guidance from healthcare bellwethers could support the sector backdrop. Litigation filed in September is an additional concern, but the snapshot gives no detail on its potential effect.